Education
About Us
Working with TipRanks
Follow Us
Bioventus (BVS)
NASDAQ:BVS
Earnings Data
Report Date
May 13, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
0.02Last Year’s EPS
0.07Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 11, 2025
|% Change Since: 3.08%
|Next Earnings Date:May 13, 2025
Earnings Call Sentiment|Positive
Bioventus demonstrated strong financial performance with significant revenue growth, improved profitability, and successful debt reduction. Challenges included a flat performance in Restorative Therapies and price sensitivity in the GELSYN product. Overall, the positives outweigh the negatives, with a promising outlook for 2025.Company Guidance
During the Bioventus Fourth Quarter 2024 Earnings Conference Call, the company provided detailed financial guidance and performance metrics for 2025. Bioventus achieved a 14% revenue increase in the fourth quarter, driven by double-digit growth across its segments. The Surgical Solutions segment outperformed with an 18% rise, notably in Ultrasonics, which saw over 20% growth for consecutive quarters. Pain Treatments also climbed 17%, with DUROLANE leading due to strong brand recognition and market execution. For 2025, Bioventus projects net sales between $560 million and $570 million, reflecting organic growth of 6% to 8%, and adjusted EBITDA between $112 million and $116 million. The company aims to expand profitability by 100 basis points and nearly double its free cash flow, building on its 2024 success where it achieved a 23% increase in adjusted EBITDA to $109 million. Bioventus also reduced its net leverage ratio to slightly above 3x, with plans to decrease it below 2.5x by year-end 2025.Strong Revenue Growth
Bioventus reported a 14% increase in revenue for the fourth quarter and 12% for the full year 2024, with organic growth of 14%.
Surgical Solutions Performance
Surgical Solutions achieved double-digit growth, with Ultrasonics experiencing its highest quarterly growth rate of the year and an 18% acceleration in revenue.
Improved Profitability
Adjusted EBITDA grew by 23% to $109 million for the year, with a 160 basis point expansion in adjusted EBITDA margin.
Debt Reduction
The company paid down nearly $50 million in debt in the fourth quarter, reducing the net leverage ratio by more than a full turn since the start of 2024.
Positive Outlook for 2025
Bioventus targets above-market growth, continued profitability expansion, and accelerated free cash flow generation for 2025.
---
BVS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
BVS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 11, 2025 | $8.76 | $10.80 | +23.29% |
| Nov 05, 2024 | $13.71 | $11.48 | -16.27% |
| Aug 06, 2024 | $6.26 | $8.09 | +29.23% |
| May 07, 2024 | $4.00 | $5.12 | +28.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Bioventus (BVS) report earnings?
Bioventus (BVS) is schdueled to report earning on May 13, 2025, TBA Not Confirmed.
What is Bioventus (BVS) earnings time?
Bioventus (BVS) earnings time is at May 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BVS EPS forecast?
BVS EPS forecast for the fiscal quarter 2025 (Q1) is 0.02.
---